3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Glioma
5
Glioblastoma
2
Brain Neoplasms
2
Stomach Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Meningeal Carcinomatosis
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid
1
Gliosarcoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Cyclophosphamide
101
Etoposide
60
Carboplatin
55
Vincristine
51
Filgrastim
49
Topotecan
44
Temozolomide
44
Melphalan
44
Isotretinoin
44
Doxorubicin
44
Irinotecan
42
Cisplatin
35
3-Iodobenzylguanidine
34
Peripheral Blood Stem Cell Transplantation
31
dinutuximab
30
Granulocyte Colony-Stimulating Factor
30
Radiotherapy
29
sargramostim
28
Granulocyte-Macrophage Colony-Stimulating Factor
25
Busulfan
22
Magnetic Resonance Spectroscopy
19
aldesleukin
18
Thiotepa
18
fludarabine
17
Interleukin-2
17
humanized 3F8 anti-GD2 monoclonal antibody
16
etoposide phosphate
16
naxitamab
15
Ifosfamide
15
Biopsy
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
Immunotherapy, Adoptive
×
CNS
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts